TAFINLAR (dabrafenib) capsules is used to treat BRAF V600E Mutation-Positive Unresectable or Metastatic Melanoma, BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma, Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma, BRAF V600E Mutation-Positive Metastatic NSCLC, BRAF V600E Mutation-Positive Metastatic NSCLC, BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors. . TAFINLAR (dabrafenib) capsules can be imported for personal use under "patient name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.
Therapeutic indications and Usage
TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. TAFINLAR is indicated, in combination with trametinib, for: • the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. • the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. • the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. • the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. • the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Medicine Name: TAFINLAR
Generic Name: dabrafenib
Approval Date: 2013
Treatment of: Melanoma...
Company Name: Novartis Pharmaceuticals Corporation.
Source Details: Patient Information
Patient Name Basis Treatment IPN, New Delhi can facilitate patient to import of "TAFINLAR (dabrafenib) capsules" in quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
Health Professional In India
If you have any question, please email IPN Support Team or Call Indian Pharma Network for TAFINLAR (dabrafenib) capsules price list or cost in India. on
Mr. Tarun:- +91 9891 296 838
Mr. Neeraj:- +91 9811 747 774
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.
TAFINLAR is a prescription medicine used alone or in combination with trametinib to treat people with a type of skin cancer called melanoma: • that has spread to other parts of the body or cannot be removed by surgery, and 35 • that has a certain type of abnormal “BRAF” gene. Your healthcare provider will perform a test to make sure that TAFINLAR is right for you. Active ingredient: dabrafenib Inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose 50 mg Capsules: Dark red capsule imprinted with ‘GS TEW’ and ‘50 mg’ available in bottles of 120 (NDC 0173-0846-08). Each bottle contains a silica gel desiccant. 75 mg Capsules: Dark pink capsule imprinted with ‘GS LHF’ and ‘75 mg’ available in bottles of 120 (NDC 0173-0847-08). Each bottle contains a silica gel desiccant. Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Source content : www.accessdata.fda.gov
IPN, New Delhi can facilitate patient to import of "TAFINLAR (dabrafenib) capsules" in quantities for personal use. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Visakhapatnam, Surat, Jaipur, Coimbatore, Kanpur, Nagpur, Raipur, Kochi, Kozhikode, Nashik, Salem, Thiruvananthapuram, Madurai, Jodhpur, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. with over 20 years of domain experience.
For procurement cost of TAFINLAR (dabrafenib) capsules in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the TAFINLAR (dabrafenib) capsules medicine cost price in India.
The order for TAFINLAR (dabrafenib) capsules will be confirmed only after
1. submitting Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
2. Permission from obtained from the office of the Drugs Controller General (India).
3. Availability of TAFINLAR (dabrafenib) capsules from authorised distributor.
Dabrafenib, sold under the brand name Tafinlar & Rafinlar ( both by Novartis) among others, is a medication for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF (V600)-mutated metastatic melanoma. The US Food and Drug Administration initially approved dabrafenib as a single agent treatment for patients with BRAF V600E mutation-positive advanced melanoma on May 29, 2013. Dabrafenib was approved for use in the European Union in August 2013. In April 2017, the European Union approved the combination of dabrafenib with trametinib for BRAF V600-positive advanced or metastatic non small-cell lung cancer (NSCLC).
TAFINLAR (dabrafenib) capsules, for subcutaneous use Initial U.S. Approval: 2017
• Capsules: 50 mg, 75 mg (3
For TAFINLAR (dabrafenib) capsulesIndications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors For More Details
Dabrafenib in Combination With Trametinib for Unresectable or Metastatic Solid Tumors With BRAF V600E Mutation For More Details
Pancreatic Cancer Awareness Month: Novel Targeted Therapy in PDAC For More Details
Step 1. Send a request for your medicine online:-Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
Step 2. Verification of documents:-We verify your a prescription and necessary documents to import drugs in quantities for personal use.
Step 3. Permission to Import:-After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.
Step 4. We source your medicine:-Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.
Step 5. Delivery of medicine:-After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.
Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.
Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.
Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.
Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.
Send your query to find out -
TAFINLAR (dabrafenib) capsules price in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
TAFINLAR (dabrafenib) capsules price in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
TAFINLAR (dabrafenib) capsules price in North America – Mexico.
TAFINLAR (dabrafenib) capsules price in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
TAFINLAR (dabrafenib) capsules price in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
TAFINLAR (dabrafenib) capsules price in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
TAFINLAR (dabrafenib) capsules price in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
TAFINLAR (dabrafenib) capsules price in Australia and New Zealand.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.